Eli Lilly Says It Warned Doctors Of Cymbalta 'Brain Zaps'

Law360, Los Angeles (April 29, 2013, 10:24 PM EDT) -- Eli Lilly & Co. urged a California federal judge on Monday to toss a class action alleging inadequate labeling of its antidepressant Cymbalta, saying it sufficiently disclosed to doctors the risk that discontinuing use of the drug would cause “brain zaps” and other side effects.

Lilly's attorney Phyllis Jones of Covington & Burling LLP said the disclosures were sufficient for the claims of four consumers, including one physician, to be dismissed under the learned intermediary doctrine, which shields a drug manufacturer from liability when it provides...
To view the full article, register now.